Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939123 | 0.88 | ALDH1A1 (0.56) | ALDH1A1HTTPARP1HRH3 | |
| SCHEMBL10263957 | 0.78 | MAPT (0.42) | MEN1KMT2AALDH1A1HTT | |
| SCHEMBL4938232 | 0.75 | PARP1 (0.43) | ALDH1A1HTTPARP1HRH3 | |
| SCHEMBL4941322 | 0.74 | PARP1 (0.43) | MEN1KMT2ADRD2DRD4ALDH1A1 | |
| SCHEMBL14282077 | 0.73 | HRH3 (0.44) | ALDH1A1HTTPARP1HRH3 | |
| SCHEMBL28169784 | 0.73 | CCR3 (0.67) | MEN1KMT2ADRD2DRD4ALDH1A1 | |
| SCHEMBL15759211 | 0.73 | THRB (0.47) | ALDH1A1 | |
| SCHEMBL4933545 | 0.73 | ALDH1A1 (0.46) | ALDH1A1HTTPARP1HRH3 | |
| SCHEMBL5795208 | 0.72 | SLC18A3 (0.57) | MEN1KMT2ADRD2DRD4CCR5 | |
| SCHEMBL10268327 | 0.71 | SLC18A3 (0.61) | MEN1KMT2ADRD2CCR5SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | claimed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | claimed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | MEN1 3148/4885KMT2A 2582/4885DRD2 592/4885 |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | HRH2, HNMT, HRH3 | MEN1 3148/4885KMT2A 2582/4885DRD2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.